Private Company Edition: Arbor is developing drugs based on proprietary gene editors, Acrivon is applying proteomics to precision cancer therapies, and bit.bio is producing differentiated cell products. Also, Marengo launches with $80m, Sanofi invests up to $60m in Gyroscope and Shasqi raises $50m.
Arbor Biotechnologies, Acrivon Therapeutics Inc. and bit.bio are the newest members of the biopharma venture capital mega-round club after the companies announced series B rounds totaling $215m, $100m and $103m, respectively.
Mega-rounds have helped start-ups and growth-stage companies build out innovative drug discovery and development platforms while advancing multiple therapeutic candidates...
Create an account to read this article
Already a subscriber?
The deal, which could be worth as much as $360m, marks the Danbury, CT-based firm's strategic expansion into cardiorenal medicine.
Mid-sized, diversified Japanese group teams up with Singaporean wholesaler Formiica and Japanese trading/contract services firm CBC for Singapore JV focused on in-licensing in Asia/Oceania.
Korean firm’s head of research talks to Scrip about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential.
